Organigram Global (OGI) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($138.0 million vs $134.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGI | RNA |
|---|---|---|
| Share price | $0.9303 | $8.07 |
| Market cap | $134.11M | $138.04M |
| 1-day change | -3.09% | +1.77% |
| YTD return | -42.86% | — |
| 1-year return | -51.02% | — |
| 5-year return | -89.29% | — |
| P/E ratio (TTM) | 2.16 | — |
| Forward P/E | 38.76 | — |
| EPS (TTM) | $0.43 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $16.77 |
| 52-week low | $0.853 | $7.63 |
| Distance from 52-week high | -58.47% | -51.88% |
| Analyst consensus | buy | none |
| Avg. price target upside | — | +209.79% |
| Average volume | 882.38K | 253.00K |
| Shares outstanding | 144.15M | 17.11M |
| Employees | 1,139 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
OGI vs RNA FAQ
Which is bigger, Organigram Global or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $138.04M compared with $134.11M for Organigram Global (OGI).
Are Organigram Global and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.